Lymphoma researchers in search of molecular targets.

摘要

"Looking at the data as it was presented to us, clearly we weren't impressed that this drug represented an advance," said Wyndham Wilson, M.D., Ph.D., chief of the lymphoma therapeutics section in the National Cancer Institute's Center for Cancer Research and one of the committee's members.